New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin

References

• Geerts WH, Bergqvist D, Pineo GF et al. Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl.), 381S–453S (2008).
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am. J. Med.119(1), 60–68 (2006).
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost.5(3), 632–634 (2007).
   PubMed Web of Science ®Google Scholar
• Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler. Thromb. Vasc. Biol.29(3), 316–320 (2009).
   PubMed Web of Science ®Google Scholar
• Segal JB, Streiff MB, Hofmann LV, Thornton K, Bass EB. Management of venous thromboembolism: a systematic review for a practice guideline. Ann. Intern. Med.146(3), 211–222 (2007).
   PubMed Web of Science ®Google Scholar
• Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med.354(14), 1477–1488 (2006).
   PubMed Web of Science ®Google Scholar
• Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev. Cardiovasc. Ther.5(3), 387–399 (2007).
   PubMedGoogle Scholar
• Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med.349(2), 146–153 (2003).
   PubMed Web of Science ®Google Scholar
• Khosravi-Shahi P, Pérez-Manga G. International recommendations for the prevention and treatment of venous thromboembolism associated with cancer. Clin. Drug. Investig.29(10), 625–633 (2009).
   PubMedGoogle Scholar
• Nightingale SL. From the Food and Drug Administration. JAMA270(14), 1672 (1993).
   PubMedGoogle Scholar
• Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest119(1 Suppl.), 64S–94S (2001).
   PubMed Web of Science ®Google Scholar
• Ryan TJ, Antman EM, Brooks NH et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J. Am. Coll. Cardiol.34(3), 890–911 (1999).
   PubMed Web of Science ®Google Scholar
• Planès A. Review of bemiparin sodium – a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin. Pharmacother.4(9), 1551–1561 (2003).
   PubMed Web of Science ®Google Scholar
• Martínez-González J, Vila L, Rodríguez C. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev. Cardiovasc. Ther.6(6), 793–802 (2008).
   PubMedGoogle Scholar
• Rocha E, Imberti D, Paschina E. Low-molecular-weight heparins: before or after surgery? New concepts and evidence: congress report from the Sigma Tau/ROVI Satellite Symposium (Rome, Italy, 13 November 2006). Clin. Drug Investig.27(5), 357–366 (2007).
   PubMedGoogle Scholar
• Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs63(21), 2357–2377 (2003).
   PubMedGoogle Scholar
• Depasse F, González de Suso MJ, Lagoutte I, Fontcuberta J, Borrell M, Samama MM. Comparative study of the pharmacokinetic profiles of two LMWH-bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)-administered subcutaneously to healthy male volunteers. Thromb. Res.109(2–3), 109–117 (2003).
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J. Thromb. Haemost.5(5), 955–962 (2007).
   PubMed Web of Science ®Google Scholar
• Antonijoan RM, Rico S, Martínez-González J et al. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. Int. J. Clin. Pharmacol. Ther.47, 726–732 (2009).
   PubMedGoogle Scholar
• Christidou FN, Frangia TK, Bamichas GI et al. Comparison of two low-molecular weight heparins (LMWH), tinzaparin and bemiparin, during hemodialysis. Int. J. Clin. Pharmacol. Ther.43(7), 335–338 (2005).
   PubMedGoogle Scholar
• Borrell M, Antonijoan RM, Ortiz R et al. Pharmacokinetic profile of two LMWH: bemiparin 3500 IU and enoxaparin 4000 IU after sc administration in healthy volunteers (18th Congress of the International Society of Thrombosis and Haemostasis. Paris, France, 2001). Thromb. Haemost.86(Suppl.), CD3578 (2001).
   Google Scholar
• Falkon L, Garí M, Sáenz-Campos D, Antonijoan R, Barbanoj M, Fontcuberta J. Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH(RO-11) in healthy subjects. Thromb. Haemost.73(4), 728–729 (1995).
   PubMedGoogle Scholar
• Falkon L, Garí M, Barbanoj M, Amiral J, Fontcuberta J. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, at therapeutic sc doses. Blood Coagul. Fibrinolysis9(2), 137–141 (1998).
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thromb. Haemost.83, 523–529 (2000).
   PubMedGoogle Scholar
• Navarro-Quilis A, Castellet E, Rocha E et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J. Thromb. Haemost.1(3), 425–432 (2003).
   PubMedGoogle Scholar
• Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics22(13), 885–894 (2004).
   PubMed Web of Science ®Google Scholar
• Abad JI, Gómez-Outes A, Martínez-González J et al. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery. Arch. Orthop. Trauma Surg.127(8), 665–670 (2007).
   PubMedGoogle Scholar
• Otero-Fernández R, Gómez-Outes A, Martínez-González J et al. Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. Clin. Appl. Thromb. Hemost.14(1), 75–83 (2008).
   PubMedGoogle Scholar
• Vavken P, Lunzer A, Grohs JG. A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. Wien. Klin. Wochenschr.121(13–14), 454–458 (2009).
   PubMedGoogle Scholar
• Balibrea JL, Altimiras J, Larruzea I et al. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int. J. Surg.5(2), 114–119 (2007).
   PubMedGoogle Scholar
• Constans M, Santamaria A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int. J. Clin. Pract.61(2), 212–217 (2007).
   PubMed Web of Science ®Google Scholar
• Miras-Parra F, Navascués-Martínez E, Gómez-Outes A et al. Utilisation and safety of bemiparin, a low-molecular-weight heparin, in medical patients: a prospective, uncontrolled cohort study. Clin. Drug Investig.25(7), 463–472 (2005).
   PubMedGoogle Scholar
• Prieto Seva AJ. Safety and effectiveness of bemiparin in the prevention of venous thromboembolic disease in nursing home patients. Rev. Esp. Geriatr. Gerontol.42, 20–26 (2007).
   Google Scholar
• Rodríguez-Mañas L, Gómez-Huelgas R, Monteagudo G, Maeso R, Gómez-Outes A, Martínez-González J. Bemiparin thromboprophylaxis in elderly medical patients: the ANCIANOS study. J. Thromb. Haemost.5(Suppl. 2), P-T-671 (2007).
   Google Scholar
• Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch. Intern. Med.164(12), 1319–1326 (2004).
   PubMedGoogle Scholar
• Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr. Opin. Pulm. Med.11(5), 373–379 (2005).
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Gebska M, Kadziola Z et al. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb. Haemost.89(4), 674–680 (2003).
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Rocha E, Martínez-González J, Kakkar VV. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics24(1), 81–92 (2006).
   PubMedGoogle Scholar
• Santamaría A, Juárez S, Reche A et al. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. Int. J. Clin. Pract.60(5), 518–525 (2006).
   PubMedGoogle Scholar
• Lecumberri R, Rosario E, Pacho J, Rocha E; FLEBUS Investigators. Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. J. Thromb. Haemost.4(11), 2504–2508 (2006).
   PubMedGoogle Scholar
• Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet366(9498), 1719–1724 (2005).
   PubMed Web of Science ®Google Scholar
• Rullan M, Cerdà L, Frontera G, Masmiquel L, Llobera J. Treatment of chronic diabetic foot ulcers with bemiparin: a randomized, triple-blind, placebo-controlled, clinical trial. Diabet. Med.25(9), 1090–1095 (2008).
   PubMedGoogle Scholar
• Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug. Dev. Res.67(2), 166–174 (2006).
   PubMed Web of Science ®Google Scholar
• Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. Modulation of gastrointestinal permeability of low-molecular-weight heparin by l-arginine: in vivo and in vitro evaluation. J. Pharm. Pharmacol.58(5), 591–598 (2006).
   PubMed Web of Science ®Google Scholar
• Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J. Control. Release113(1), 38–42 (2006).
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Maincent P. Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur. J. Pharm. Biopharm.67(3), 632–638 (2007).
   PubMed Web of Science ®Google Scholar
• Lanke SS, Gayakwad SG, Strom JG, D’Souza MJ. Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system. J. Microencapsul.S26(6), 493–500 (2009).
   Google Scholar
• Scala-Bertola J, Gajdziok J, Rabisková M et al. Pellets for oral administration of low-molecular-weight heparin. Drug Dev. Ind. Pharm.35(12), 1503–1510 (2009).
   PubMed Web of Science ®Google Scholar
• Scala-Bertola J, Rabiskova M, Lecompte T, Bonneaux F, Maincent P. Granules in the improvement of oral heparin bioavailability. Int. J. Pharm.374(1–2), 12–16 (2009).
   PubMed Web of Science ®Google Scholar
• Siragusa S, Arcara C, Malato A et al. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann. Oncol.16(Suppl. 4), iv136– iv139 (2005).
   PubMedGoogle Scholar
• Agnelli G, Gussoni G, Bianchini C et al.; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol.10(10), 943–949 (2009).
   PubMed Web of Science ®Google Scholar
• Calderero Aragón V, de Gregorio Ariza MA, Pazo Cid R et al. Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter. Med. Clin. (Barc).133(10), 365–370 (2009).
   PubMedGoogle Scholar
• Rashid ST, Thursz MR, Razvi NA et al. Venous thromboprophylaxis in UK medical inpatients. J. R. Soc. Med.98(11), 507–512 (2005).
   PubMed Web of Science ®Google Scholar
• Arbit E, Goldberg M, Gomez-Orellana I, Majuru S. Oral heparin: status review. Thromb. J.4, 6 (2006).
   PubMedGoogle Scholar